



Department of  
**Health**

An Roinn Sláinte

Máinnystrie O Poustie

[www.health-ni.gov.uk](http://www.health-ni.gov.uk)

**For Action:** Assistant Director Integrated Care, Head of Pharmacy and Medicines Management, HSC Board & BSO  
Heads of Pharmacy and Medicines Management of HSC Trusts  
Regulation Quality Improvement Authority

From: Chief Pharmaceutical Officer  
Mrs Cathy Harrison  
Castle Buildings  
Upper Newtownards Road  
Belfast BT4 3SQ

Telephone: 028 90 523219  
Facsimile: 028 90 522335

E-Mail: [cathy.harrison@health-ni.gov.uk](mailto:cathy.harrison@health-ni.gov.uk)

Our Ref: PHC-26-2021  
Date: 12 October 2021

**MEDICINES RECALL**  
**CLASS 2 MEDICINES RECALL**  
**Action Within 48 Hours**  
**Patient/Retail/Wholesaler Level Recall**

Dear Healthcare Professional

**Wrafton Laboratoires Limited (trading as Perrigo)**

**Tesco Flu-Max All In One Chesty Cough & Cold  
Powder for Oral Solution**

**PL 12063/0104**

Batch Number	Expiry Date	Pack Size	First Distributed
9MW0145	Nov 2022	10s	16 Mar 2020
0CW0054	Jan 2023	10s	07 Apr 2020
0FW0133	May 2023	10s	12 May 2021

Active Pharmaceutical Ingredients: Paracetamol 1000 mg/sachet; Guaifenesin 200 mg/sachet; Phenylephrine hydrochloride 12.2 mg/sachet

**Brief description of the problem**

Perrigo are recalling the above batches due to an error on the sachet contained within the outer carton. The sachet artwork incorrectly states that children aged 12 years and over can take 4 sachets containing 1000mg of paracetamol in 4 doses over a 24 hour period, whereas the carton, PIL and SmPC state that the product is not to be given to the under 16s. The sachets dosage instructions are those which were in use prior to the paediatric paracetamol posology update implemented by the MHRA.

The correct posology instruction on the outer carton, patient information leaflet (PIL) and summary of product characteristics (SmPC) comply with regulatory requirements but differ from that on the product sachet which is incorrect. [See link to PIL containing the correct information](#)

**This product should not be given to under 16s and therefore the product is being recalled from patients directly.**

This product is only sold from Tesco stores directly and does not impact any other products that share the PL number, but packaged in different liveries. If you have any concerns, please contact Perrigo using the details below.

**Advice for patients and consumers**

- Stop using the product immediately and return this to Tesco Stores.
- If you experience any side-effects, or have any questions or concerns about your health, speak to your doctor or pharmacist.
- Report any suspected side effects via the [Yellow Card Scheme](#)

**Advice for retailers and wholesalers**

- Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

**Advice for healthcare professionals**

- Advise patients who have been supplied this product to stop using the product immediately and return this to Tesco Stores, where appropriate.
- Any suspected side effects should be reported via the [Yellow Card Scheme](#)

**Further Information**

For more information, please contact: Perrigo Customer Services Team on 0203 598 9603 or [UKLOCustomerService@perrigo.com](mailto:UKLOCustomerService@perrigo.com)

For stock control queries, please contact: Perrigo Service Team on 01226 704711 or [customerservice@perrigouk.com](mailto:customerservice@perrigouk.com)

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this notice.

RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Yours sincerely



Mrs Cathy Harrison  
Chief Pharmaceutical Officer